72 related articles for article (PubMed ID: 19037032)
1. Prevention of developmental delays in a Down syndrome mouse model.
Toso L; Cameroni I; Roberson R; Abebe D; Bissell S; Spong CY
Obstet Gynecol; 2008 Dec; 112(6):1242-1251. PubMed ID: 19037032
[TBL] [Abstract][Full Text] [Related]
2. Novel insights from fetal and placental phenotyping in 3 mouse models of Down syndrome.
Adams AD; Hoffmann V; Koehly L; Guedj F; Bianchi DW
Am J Obstet Gynecol; 2021 Sep; 225(3):296.e1-296.e13. PubMed ID: 33766516
[TBL] [Abstract][Full Text] [Related]
3. Spatiotemporal development of spinal neuronal and glial populations in the Ts65Dn mouse model of Down syndrome.
Aziz NM; Klein JA; Brady MR; Olmos-Serrano JL; Gallo V; Haydar TF
J Neurodev Disord; 2019 Dec; 11(1):35. PubMed ID: 31839007
[TBL] [Abstract][Full Text] [Related]
4. Understanding the mechanism of learning enhancement: NMDA and GABA receptor expression.
Toso L; Johnson A; Bissell S; Roberson R; Abebe D; Spong CY
Am J Obstet Gynecol; 2007 Sep; 197(3):267.e1-4. PubMed ID: 17826414
[TBL] [Abstract][Full Text] [Related]
5. Embryonic statistical analyses reveal 2 growth phenotypes in mouse models of Down syndrome.
Adams AD; Lin J; Bianchi DW; Bishop L; Sato T; Baxter LL; Hoffmann V; Koehly L; Guedj F
Am J Obstet Gynecol; 2024 Feb; 230(2):258.e1-258.e11. PubMed ID: 37544351
[TBL] [Abstract][Full Text] [Related]
6. Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse model.
Llambrich S; Tielemans B; Saliën E; Atzori M; Wouters K; Van Bulck V; Platt M; Vanherp L; Gallego Fernandez N; Grau de la Fuente L; Poptani H; Verlinden L; Himmelreich U; Croitor A; Attanasio C; Callaerts-Vegh Z; Gsell W; Martínez-Abadías N; Vande Velde G
Elife; 2024 Mar; 12():. PubMed ID: 38497812
[TBL] [Abstract][Full Text] [Related]
7. Erythropoiesis Stimulating Agents Demonstrate Safety and Show Promise as Neuroprotective Agents in Neonates.
Ohls RK; Christensen RD; Widness JA; Juul SE
J Pediatr; 2015 Jul; 167(1):10-2. PubMed ID: 25917767
[No Abstract] [Full Text] [Related]
8. Enhanced GIRK2 channel signaling in Down syndrome: A feasible role in the development of abnormal nascent neural circuits.
Kleschevnikov AM
Front Genet; 2022; 13():1006068. PubMed ID: 36171878
[TBL] [Abstract][Full Text] [Related]
9. DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients.
Moreau M; Carmona-Iragui M; Altuna M; Dalzon L; Barroeta I; Vilaire M; Durand S; Fortea J; Rebillat AS; Janel N
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740400
[TBL] [Abstract][Full Text] [Related]
10. The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives.
Stagni F; Bartesaghi R
Front Cell Neurosci; 2022; 16():903729. PubMed ID: 35634470
[TBL] [Abstract][Full Text] [Related]
11. Luteolin induces hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome.
Zhou WB; Miao ZN; Zhang B; Long W; Zheng FX; Kong J; Yu B
Neural Regen Res; 2019 Apr; 14(4):613-620. PubMed ID: 30632501
[TBL] [Abstract][Full Text] [Related]
12. Potential Role of Microtubule Stabilizing Agents in Neurodevelopmental Disorders.
Bonini SA; Mastinu A; Ferrari-Toninelli G; Memo M
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933765
[TBL] [Abstract][Full Text] [Related]
13. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome.
Kazim SF; Blanchard J; Bianchi R; Iqbal K
Sci Rep; 2017 Apr; 7():45561. PubMed ID: 28368015
[TBL] [Abstract][Full Text] [Related]
14. Absence of Prenatal Forebrain Defects in the Dp(16)1Yey/+ Mouse Model of Down Syndrome.
Goodliffe JW; Olmos-Serrano JL; Aziz NM; Pennings JL; Guedj F; Bianchi DW; Haydar TF
J Neurosci; 2016 Mar; 36(10):2926-44. PubMed ID: 26961948
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal measures of cognition in the Ts65Dn mouse: Refining windows and defining modalities for therapeutic intervention in Down syndrome.
Olmos-Serrano JL; Tyler WA; Cabral HJ; Haydar TF
Exp Neurol; 2016 May; 279():40-56. PubMed ID: 26854932
[TBL] [Abstract][Full Text] [Related]
16. Timing of therapies for Down syndrome: the sooner, the better.
Stagni F; Giacomini A; Guidi S; Ciani E; Bartesaghi R
Front Behav Neurosci; 2015; 9():265. PubMed ID: 26500515
[TBL] [Abstract][Full Text] [Related]
17. New Perspectives for the Rescue of Cognitive Disability in Down Syndrome.
Bartesaghi R; Haydar TF; Delabar JM; Dierssen M; Martínez-Cué C; Bianchi DW
J Neurosci; 2015 Oct; 35(41):13843-52. PubMed ID: 26468184
[TBL] [Abstract][Full Text] [Related]
18. Sera from children with autism induce autistic features which can be rescued with a CNTF small peptide mimetic in rats.
Kazim SF; Cardenas-Aguayo Mdel C; Arif M; Blanchard J; Fayyaz F; Grundke-Iqbal I; Iqbal K
PLoS One; 2015; 10(3):e0118627. PubMed ID: 25769033
[TBL] [Abstract][Full Text] [Related]
19. Chronic P7C3 treatment restores hippocampal neurogenesis in the Ts65Dn mouse model of Down Syndrome [Corrected].
Latchney SE; Jaramillo TC; Rivera PD; Eisch AJ; Powell CM
Neurosci Lett; 2015 Mar; 591():86-92. PubMed ID: 25668489
[TBL] [Abstract][Full Text] [Related]
20. Prospects for improving brain function in individuals with Down syndrome.
Costa AC; Scott-McKean JJ
CNS Drugs; 2013 Sep; 27(9):679-702. PubMed ID: 23821040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
